Zoetis reported an 11% year-over-year decline in US companion animal sales in Q1, mainly due to generic competition affecting key drugs like Convenia and Cerenia. Despite some growth in international and livestock segments, the company faces ongoing structural challenges from patent expirations. The stock has dropped 30%, and the analyst downgraded Zoetis to Hold, awaiting signs of revenue stabilization as the impact of generics eases in coming quarters.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud and other unlawful practices following the company's announcement of a profit guidance cut for 2026. Zoetis reported flat net income of $601 million for Q1 ...
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-ye...
Zoetis, once a high-performing stock, has fallen about 70% from its peak in December 2021, mainly because its U.S. companion animal business saw an 11% organic decline in Q1 2026 after strong growth in 2021. The decline is linked to weaker U.S. consu...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
